Not required for Clinical Vignette.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.5603/ep.99763 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
[68Ga]Ga-DOTA-TATE in diagnosis of MEN syndrome.
Endokrynol Pol
August 2024
Nuclear Medicine Department, Medical University of Warsaw, Warsaw, Poland.
Not required for Clinical Vignette.
View Article and Find Full Text PDFClinical impact of using [F]AlF-NOTA-octreotide PET/CT instead of [Ga]Ga-DOTA-SSA PET/CT: Secondary endpoint analysis of a multicenter, prospective trial.
J Neuroendocrinol
August 2024
Department of Imaging and Pathology, Nuclear Medicine, University Hospitals Leuven & Nuclear Medicine and Molecular Imaging, KU Leuven, Leuven, Belgium.
[F]AlF-NOTA-octreotide ([F]AlF-OC) is a promising alternative for [Ga]Ga-DOTA-somatostatin analogs (SSAs) in positron emission tomography (PET) imaging of the somatostatin receptor (SSTR). Our aim is to assess changes in TNM staging and differences in patient management between [F]AlF-OC PET/CT and [Ga]Ga-DOTA-SSA PET/CT in the work-up of neuroendocrine tumor (NET) patients. Patients who underwent both [F]AlF-OC and [Ga]Ga-DOTA-TATE or [Ga]Ga-DOTA-NOC PET/CT in our multicenter study (Pauwels et al.
View Article and Find Full Text PDFSomatostatin Receptor Imaging in Mice with Difference Positive Rate of SSTR2.
Neuroendocrinology
September 2024
State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancer, Beijing Key Laboratory of Carcinogenesis and Translational Research, NMPA Key Laboratory for Research and Evaluation of Radiopharmaceuticals (National Medical Products Administration), Department of Nuclear Medicine, Peking University Cancer Hospital and Institute, Beijing, China.
Introduction: Imaging with [68Ga]Ga-DOTA-TATE, [68Ga]Ga-DOTA-JR11, and [18F]AlF-NOTA-JR11 was performed to analyze differences among the three probes and to analyze the correlation between the image and pathology parameters.
Method: Tumor-bearing mice with different positive rates of somatostatin receptor II (SSTR2) were established with HEK293-SSTR2 and HEK293 cells, and imaging was performed on the same mouse with [68Ga]Ga-DOTA-TATE, [68Ga]Ga-DOTA-JR11, and [18F]AlF-NOTA-JR11 at 20, 60, and 120 min. The image parameters were obtained, including the maximum standard uptake value (SUVmax), mean standard uptake value (SUVmean), standard deviation of SUVmean, tumor volume, and coefficient of variation (CoV).
Study protocol of LANTana: a phase Ib study to investigate epigenetic modification of somatostatin receptor-2 with ASTX727 to improve therapeutic outcome with [177Lu]Lu-DOTA-TATE in patients with metastatic neuroendocrine tumours, UK.
BMJ Open
October 2023
Department of Surgery and Cancer, Hammersmith Hospital, London, UK
Introduction: Suitability for peptide receptor radionuclide therapy (PRRT) for neuroendocrine neoplasia (NENs) depends on presence of somatostatin receptor-2 (SSTR2) determined by [68Ga]Ga-DOTA-peptide-positron emission tomography (PET). Some patients have low or no uptake on [68Ga]Ga-DOTA-peptide-PET, precluding PRRT. The upstream promoter region of SSRT2 is methylated, with percentage of methylation correlating with SSTR2 expression.
View Article and Find Full Text PDFPotential value of pre- and post-therapy [68Ga]Ga-DOTA-TATE PET/CT in the prognosis of response to PRRT in disseminated neuroendocrine tumors.
Front Endocrinol (Lausanne)
September 2022
Chair and Department of Endocrinology, Jagiellonian University Medical College, Krakow, Poland.
Background: Peptide receptor radionuclide therapy (PRRT) is one of the most effective therapeutic options for the treatment of metastatic, well-differentiated neuroendocrine tumors (NETs). It improves progressive disease-free survival and enables the control of hormone secretion in functioning tumors.Currently, there are no clearly established predictors of response to PRRT.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!